BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 18, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sector
Home » Topics » BioWorld Asia

BioWorld Asia
BioWorld Asia RSS Feed RSS

Appointments and advancements for December 10, 2024

Dec. 10, 2024
New hires and promotions in biopharma in Asia-Pacific, including: Servatus.
Read More
Jun R. Huh at Healthcare Innovation Forum 2024

HIF 2024: Immune system could be key to neurodegenerative disease

Dec. 3, 2024
By Marian (YoonJee) Chu
Our immune cells are not just “defenders” against deadly viruses and pathogens but also a great balancer for tissue homeostasis. For neurological disorders, understanding the neuro-immune axis could be key to treating previously untreatable conditions such as autism spectrum disorder, according to Jun R. Huh, professor of immunology at Harvard Medical School.
Read More
Digital handshake

Tolerogenic assets at heart of Cour-Genentech $940M autoimmune deal

Dec. 3, 2024
By Karen Carey
During a busy day of dealmaking, Cour Pharmaceutical Development Co. Inc. entered a pact with Roche Holding AG’s Genentech unit to advance tolerogenic nanoparticle treatments for an autoimmune disease indication, garnering up to $940 million in up-front and milestone payments. Cour’s partnership with Genentech is its biggest to date, and the largest deal announced by a biopharma company on Dec. 3. A total of seven deals amounted to a combined single-day deal value of $3.67 billion.
Read More
Celltrion building and skyline

Celltrion to expand CRDMO business, hit ₩10T sales in 2027

Dec. 3, 2024
By Marian (YoonJee) Chu
South Korean billionaire and chairman of Celltrion Group Jungjin Seo is returning Celltrion Inc. to its contract manufacturing organization (CMO) roots, as it relies on biosimilar sales to anchor the company in a fiercely competitive novel drug R&D arena.
Read More

PYC advances PYC-003 to clinic for polycystic kidney disease

Dec. 3, 2024
By Tamra Sami
After raising AU$40 million (US$25.9 million) earlier this year to advance lead candidate VP-001 for treating retinitis pigmentosa type 11, PYC Therapeutics is now advancing PYC-003 to the clinic for polycystic kidney disease.
Read More

Regulatory actions for December 3, 2024

Dec. 3, 2024
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Beigene, Kelun-Biotech.
Read More

In the clinic for December 3, 2024

Dec. 3, 2024
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: S. Biomedics, SCG Cell Therapy.
Read More
Gastrointestinal

EA-3571, a dual inhibitor of enteropeptidase and trypsin with efficacy in mouse model of MASH

Dec. 3, 2024
Recently presented preclinical data show that EA Pharma Co. Ltd.'s EA-3571 is a highly potent dual inhibitor of enteropeptidase and trypsin with luminal action, resulting in potential anti-insulin resistance and fat-burning properties.
Read More
Scanning electron micrograph of Lassa virus budding off a cell
Infection

New fighter entering the arenavirus arena

Dec. 3, 2024
By Coia Dulsat
Researchers from Emory University, the U.S. CDC and collaborators have identified a broad-spectrum antiviral agent able to combat highly pathogenic arenaviruses. The compound, a ribonucleoside analogue that acts through RdRp inhibition, exhibited a good pharmacokinetic profile, oral bioavailability and tissue distribution in guinea pigs, while protecting animals from lethal challenges with Lassa and Junín viruses, even at very low doses.
Read More

Financings for December 3, 2024

Dec. 3, 2024
Biopharmas in Asia-Pacific raising money in public or private financings: Kanglin.
Read More
Previous 1 2 … 69 70 71 72 73 74 75 76 77 … 1457 1458 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 17, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 17, 2025.
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing